Perspectives

The future of health analytics

Unlocking clinical and business value

The recent explosion of data volume, consolidation within the industry, and government requirements have created a “perfect storm” for analytics in the health care industry. What potential does analytics hold for organizations?

Using analytics to improve value

Each new wave of technological innovation has produced an exponential growth of data volume for health care organizations. Increase in data volume has led to an increase in the need to capture and process it. Along with the lack of a streamlined process, consolidation within the health care industry has exacerbated access and availability problems. Government compliance and coding requirements have contributed to make this a “perfect storm” for analytics in the health care industry.

Furthermore, organizations view problems around widespread implementation and adoption as insurmountable obstacles. Fortunately, industry stakeholders are starting to see solutions and advancements that may produce a sea-change.

Unifying the relationship between physicians and patients

More than 40 senior executives representing health care providers, payers, innovators, life sciences organizations, and government convened at the MIT Media Lab in Boston, MA for a dialogue on the future of health analytics. They discussed challenges, opportunities, and actionable approaches to using health analytics and health data to improve clinical outcomes and business value.

The primary challenges and opportunities may be grouped into the following areas:

  • The science and art of health analytics
  • Barriers to analytics adoption
  • Disruptive developments
  • The empowered patient

Download the PDF to discover how making data actionable can help unify the relationship between physicians and patients.

When we look for near term low hanging fruit to improve the cost and quality of care, perhaps instead of only new drugs, we need software and algorithms for intervening with patients to better utilize the pharmacopeia we have. The potential for disruption is when behavioral interventions can garner measurably competitive incentive value with devices, procedures, and drugs.

Brigham Hyde, Chief Data Officer, Decision Resources Group

Contacts

Chris Park
Principal
Strategy and Operations National Leader
Deloitte Consulting LLP


David Shrier
Managing Director
Connection Science Massachusetts Institute of Technology


Brigham Hyde
Chief Data Officer
Decision Resources Group

Did you find this useful?